Nevro Corp. announced a series of data presentations supporting the use of the company's HFX 10 kHz Therapy for patients with chronic pain. Results will be presented at the 2023 North American Neuromodulation Society (NANS) Annual Meeting held from January 12-15, 2023.
A total of 18 scientific abstracts reviewing clinical results for 10 kHz Therapy, including two late-breaking presentations, seven podium presentations, and nine posters, will be presented at NANS 2023. This year, Nevro will showcase its comprehensive HFX spinal cord stimulation (SCS) portfolio, including its new AI-enabled HFX iQ system and support services for the treatment of chronic back and leg pain, including non-surgical back pain (NSBP), and painful diabetic neuropathy (PDN) at exhibit booth #824. Painful Diabetic Neuropathy (PDN): Nevro's PDN data presentation ("10 kHz SCS Provides Durable Pain Relief for Patients with Painful Diabetic Neuropathy") will highlight complete 24-month follow-up results for pain relief and improved neurological function.
Nevro's SENZA-PDN trial is the largest, Level 1 randomized controlled trial (RCT) of spinal cord stimulation (SCS) treatment studying PDN completed thus far with 216 randomized subjects. Non-Surgical Back Pain (NSBP): Nevro's NSBP data presentation ("Treating Non-surgical Refractory Back Pain with 10kHz Spinal Cord Stimulation: 24 Month Follow-up from RCT") will feature 24-month outcomes from its SENZA-NSRBP RCT investigating 10 kHz Therapy for treating non-surgical refractory back pain, with 159 randomized participants from 15 study centers. A second NSBP data presentation ("10kHz Spinal Cord Stimulation for Non-Surgical Refractory Back Pain: Objective Functional Outcome to 24-Months") will feature the important improvements in non-pain outcomes such as sleep, mental health and function experienced by patients treated with 10 kHz Therapy in the SENZA-NSRBP RCT.
10-Year Real-World Data on Efficacy of 10 kHz Therapy: In addition to the data presentations described above, a poster presentation ("Ten-Year Real-World Data on the Efficacy of High-Frequency 10 kHz Spinal Cord Stimulation") will feature 10-year follow-up data from patients who originally participated in the SENZA EU study and continued with usual care in a real-world setting over a mean period of 10 years.